HPV Symptoms: What Most People Experience (and Don't)

Why is HPV usually invisible?

HPV — human papillomavirus — encompasses more than 200 strains, with a subset affecting genital and oral tissue. For the vast majority of people, the immune system clears the infection within one to two years without any symptoms, discomfort, or visible sign 1Ref 1Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA (2021).Sexually Transmitted Infections Treatment Guidelines, 2021.HPV strain classification (types 6 and 11 for warts vs. 16 and 18 for high-risk cancer changes); typical immune clearance within one to two years; immunocompromised patients' higher risk of persistent infection; smoking as a persistence risk factor; pregnancy effects on genital warts and cervical screening safety. This is true even for strains associated with cancer-causing cellular changes. Absence of symptoms does not mean absence of infection, which is why regular screening — not symptom-watching — is the standard of care 2Ref 2US Preventive Services Task Force (2018).Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.Cervical cancer screening recommendations by age; HPV co-testing schedule; Pap smear starting at age 21 for people with a cervix; basis for the statement that screening rather than symptom-watching is the standard of care3Ref 3American College of Obstetricians and Gynecologists (2023).Colposcopy and Cervical Biopsies (Patient FAQ).HPV co-testing and Pap smear as tools for detecting cervical dysplasia before symptoms occur; colposcopy follow-up pathway for abnormal results; patient-facing explanation of what the process involves.

HPV is the most common sexually transmitted infection in the United States. Most sexually active people will have at least one HPV infection in their lifetime. This does not mean most people will develop cancer or warts — for the large majority, the infection resolves unnoticed.

When does HPV cause something you can see or feel?

Genital warts: Caused by low-risk HPV strains — most commonly types 6 and 11 1Ref 1Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA (2021).Sexually Transmitted Infections Treatment Guidelines, 2021.HPV strain classification (types 6 and 11 for warts vs. 16 and 18 for high-risk cancer changes); typical immune clearance within one to two years; immunocompromised patients' higher risk of persistent infection; smoking as a persistence risk factor; pregnancy effects on genital warts and cervical screening safety. Warts may appear on the genitals, inner thighs, around or inside the anus, or inside the vagina or cervix. They are typically soft, skin-colored, painless, and may appear weeks to months (sometimes longer) after exposure. Some people notice mild itching. These low-risk strains do not cause cervical cancer.

Cellular dysplasia (pre-cancerous changes): High-risk HPV strains — particularly types 16 and 18 — can, over many years, cause abnormal cell changes in the cervix, vulva, vagina, anus, penis, or throat 1Ref 1Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA (2021).Sexually Transmitted Infections Treatment Guidelines, 2021.HPV strain classification (types 6 and 11 for warts vs. 16 and 18 for high-risk cancer changes); typical immune clearance within one to two years; immunocompromised patients' higher risk of persistent infection; smoking as a persistence risk factor; pregnancy effects on genital warts and cervical screening safety. These changes almost never produce noticeable symptoms in their early, treatable stages. That is precisely why Pap smears and HPV co-tests exist — to detect changes before symptoms appear 2Ref 2US Preventive Services Task Force (2018).Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.Cervical cancer screening recommendations by age; HPV co-testing schedule; Pap smear starting at age 21 for people with a cervix; basis for the statement that screening rather than symptom-watching is the standard of care3Ref 3American College of Obstetricians and Gynecologists (2023).Colposcopy and Cervical Biopsies (Patient FAQ).HPV co-testing and Pap smear as tools for detecting cervical dysplasia before symptoms occur; colposcopy follow-up pathway for abnormal results; patient-facing explanation of what the process involves.

What HPV does not cause

HPV does not cause the burning, discharge, or painful sores associated with other sexually transmitted infections like chlamydia, gonorrhea, or herpes 4Ref 4US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, et al. (2021).Screening for Chlamydia and Gonorrhea: US Preventive Services Task Force Recommendation Statement.Other STI causes — chlamydia and gonorrhea — of discharge, burning, and sores that HPV does not cause; the contrast used to explain what HPV does not look like. If those symptoms are present, they point to different causes worth evaluating separately. Removing genital warts addresses the wart itself — not the underlying virus, which the immune system handles on its own timeline. Treatment of warts does not require eradicating the virus; it reduces visible lesions and may lower transmission risk.

Who should get screened, and when?

Routine Pap smears and HPV co-testing are recommended starting at age 21 for people with a cervix, on a schedule a clinician will advise based on age and prior results 2Ref 2US Preventive Services Task Force (2018).Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.Cervical cancer screening recommendations by age; HPV co-testing schedule; Pap smear starting at age 21 for people with a cervix; basis for the statement that screening rather than symptom-watching is the standard of care3Ref 3American College of Obstetricians and Gynecologists (2023).Colposcopy and Cervical Biopsies (Patient FAQ).HPV co-testing and Pap smear as tools for detecting cervical dysplasia before symptoms occur; colposcopy follow-up pathway for abnormal results; patient-facing explanation of what the process involves. The general recommendation is:

• Ages 21 to 29: Pap smear every 3 years
• Ages 30 to 65: Pap plus HPV co-test every 5 years (preferred), or Pap alone every 3 years

Outside of routine screening, see a clinician if you notice any new growths or bumps in the genital area. People who are immunocompromised — including those living with HIV or on immunosuppressive medications — are less likely to clear HPV spontaneously and typically need more frequent screening 1Ref 1Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA (2021).Sexually Transmitted Infections Treatment Guidelines, 2021.HPV strain classification (types 6 and 11 for warts vs. 16 and 18 for high-risk cancer changes); typical immune clearance within one to two years; immunocompromised patients' higher risk of persistent infection; smoking as a persistence risk factor; pregnancy effects on genital warts and cervical screening safety.

Does the HPV vaccine prevent symptoms?

The HPV vaccine (Gardasil 9) protects against the strains most responsible for genital warts (types 6 and 11) and the majority of HPV-related cancers (types 16, 18, and others) 5Ref 5Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE (2019).Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices.HPV vaccine protection against types 6, 11, 16, and 18; greatest efficacy before any exposure; adult catch-up vaccination recommendations; vaccination does not replace ongoing cervical cancer screening. It is most effective when given before any HPV exposure. The ACIP recommends routine vaccination through age 26, and shared clinical decision-making for adults ages 27 to 45 5Ref 5Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE (2019).Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices.HPV vaccine protection against types 6, 11, 16, and 18; greatest efficacy before any exposure; adult catch-up vaccination recommendations; vaccination does not replace ongoing cervical cancer screening. For people who have never been vaccinated, the vaccine still provides meaningful protection even if prior HPV exposure has occurred, because it likely protects against strains not yet encountered. Vaccination does not replace routine cervical screening 2Ref 2US Preventive Services Task Force (2018).Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.Cervical cancer screening recommendations by age; HPV co-testing schedule; Pap smear starting at age 21 for people with a cervix; basis for the statement that screening rather than symptom-watching is the standard of care3Ref 3American College of Obstetricians and Gynecologists (2023).Colposcopy and Cervical Biopsies (Patient FAQ).HPV co-testing and Pap smear as tools for detecting cervical dysplasia before symptoms occur; colposcopy follow-up pathway for abnormal results; patient-facing explanation of what the process involves.

Factors that affect HPV infection and persistence

Immune status: People with weakened immune systems — including those living with HIV or taking immunosuppressive medications — are less likely to clear HPV and may develop more persistent infection or dysplasia, making more frequent screening important 1Ref 1Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA (2021).Sexually Transmitted Infections Treatment Guidelines, 2021.HPV strain classification (types 6 and 11 for warts vs. 16 and 18 for high-risk cancer changes); typical immune clearance within one to two years; immunocompromised patients' higher risk of persistent infection; smoking as a persistence risk factor; pregnancy effects on genital warts and cervical screening safety.

Smoking: Smoking impairs the local immune response in cervical tissue and is associated with a higher likelihood that HPV infection will persist rather than clear 1Ref 1Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA (2021).Sexually Transmitted Infections Treatment Guidelines, 2021.HPV strain classification (types 6 and 11 for warts vs. 16 and 18 for high-risk cancer changes); typical immune clearance within one to two years; immunocompromised patients' higher risk of persistent infection; smoking as a persistence risk factor; pregnancy effects on genital warts and cervical screening safety.

Pregnancy: Genital warts may grow more rapidly during pregnancy due to hormonal changes. Cervical screening is safe during pregnancy, and results guide management of any abnormal findings 1Ref 1Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA (2021).Sexually Transmitted Infections Treatment Guidelines, 2021.HPV strain classification (types 6 and 11 for warts vs. 16 and 18 for high-risk cancer changes); typical immune clearance within one to two years; immunocompromised patients' higher risk of persistent infection; smoking as a persistence risk factor; pregnancy effects on genital warts and cervical screening safety.